SciNeuro Pharma inks antibody licensing deal with Lilly
China’s SciNeuro Pharmaceuticals has entered into an exclusive license agreement with US pharma major Eli Lilly (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
Under the terms of the accord, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China. Lilly will receive an undisclosed upfront cash payment, in addition to downstream milestones and royalties on products developed and commercialized by SciNeuro. Lilly retains all rights outside Greater China.
SciNeuro launched in December 2020 with a $100 million Series A financing co-led by Lilly Asia Ventures Fund and Arch Venture Partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze